Rakovina Therapeutics Inc · TSXV:RKV
Rakovina Therapeutics — Investor Presentation (May 2025)
19 slides from Rakovina Therapeutics's investor presentation, May 2025
Slide 1: Advancing Cancer Care with the Precision & Power of AI
ADVANCING CANCER CARE WITH THE PRECISION & POWER OF AI TSX.V: RKV Investor Presentation | Q2 2025
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the terms of the private placement, the closing of the private placement, the investors who will pa
Slide 3: Accelerating Drug Discovery to Save Lives
ACCELERATING DRUG DISCOVERY TO SAVE LIVES Our mission has always been about improving the lives of those battling cancer. Now, with a robust Artificial Intelligence (AI) platform on our side, we are moving into a new era of research speed and accuracy. Using Best in Class AI algorithms, we quickly a
Slide 4: Rakovina Therapeutics Powered by AI: Investment Thesis
RAKOVINA INVESTMENT THESIS THERAPEUTICS POWERED BY AI FOCUSED ON DDR RESPONSE-BASED THERAPIES Founded in 2021 to focus on the development of new DNA-damage (DDR) response-based therapies for the treatment of cancer EXCLUSIVE ACCESS TO BEST-IN-CLASS AI PLATFORMS Exclusive access to utilize the Deep D
Slide 5: Experienced Team with a Track Record of Success
EXPERIENCED TEAM WITH A TRACK RECORD OF SUCCESS Our team has extensive expertise in drug discovery, preclinical and clinical development and partnering to advance breakthrough innovations to become potential life-changing treatments in the oncology field. JEFFREY BACHA, BSC, MBA ARTEM CHERKASOV, PHD
Slide 6: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD DENNIS BROWN, PHD LEONARD POST, PHD Chair, Scientific Advisory Board SAB/Senior Drug Development (SAB)/Director Advisor • Involved in cancer drug discovery and development for 35+ years and currently • 35+ years of drug development and leadership experience in the pharmaceu
Slide 7: Rakovina Therapeutics AI Powered Drug Development
RAKOVINA THERAPEUTICS AI POWERED DRUG DEVELOPMENT Patients can not wait years to get the treatment they need today and tomorrow. Traditional Drug Development AI Driven Drug Development Thousands of potential drug BILLIONS of potential drug candidates candidates DEVELOPMENT PATH STAGE 1 Selecting a S
Slide 8: A New Era with Drug Discovery Through AI
HOW IT WORKS A NEW ERA WITH Deep Docking1 and EnkiTM DRUG DISCOVERY are distinct computational THROUGH AI modeling techniques to rapidly evaluate billions of COLLABORATIONS compounds to identify novel • Exclusive access to Deep Docking1 AI therapeutic drug platform for DNA-damage response targets ca
Slide 9: Deep Docking AI Platform: Real-World Impact on COVID-19
DEEP DOCKING1 AI PLATFORM: REAL-WORLD IMPACT ON COVID- 19 The team behind Deep Docking partnered with Nvidia, Dell and UBC Advanced Research Computing (ARC) to identify potential COVID- 19 therapeutics from large libraries. “Even with a supercomputer, it would take years to screen billions of compou
Slide 10: DNA-Damage Response (DDR) $18B
75% of solid tumors harbor a DDR defect1 DNA-DAMAGE RESPONSE (DDR) • DDRs are naturally occurring mechanisms that • detect and repair DNA damage within our cells. Many cancers harbor a defect in these natural $18B DDR annual market potential by 20302 repair mechanisms allowing mutations to accumulat
Slide 11: Combining AI Platforms with Rakovina Capabilities for Rapid DDR Drug Development
COMBINING AI PLATFORMS WITH RAKOVINA CAPABILITIES FOR RAPID DDR DRUG DEVELOPMENT COMPOUND SCREENING & LEAD OPTIMIZATION PHASE only 3-4 months from 3 years COMPOUND SCREENING DRUG VALIDATION QUALIFIED CLINICAL LAB LEADS 5B+ ULTRA LARGE INTEGRATED PLATFORM FOR ADVANCING DDR DRUG DATASETS FOR DRUG DDR
Slide 12: First AI DDR Target: CNS Penetrant Selective Inhibitor of PARP-1
FIRST AI DDR TARGET: A CNS PENETRANT SELECTIVE INHIBITOR OF PARP-1 • PARP is a type of enzyme that helps repair DNA damage in cells. • PARP inhibitors are a type of drug that works by preventing certain types of cancer cells from repairing damaged DNA, committing them to die. • 1st generation PARP-1
Slide 13: Second AI DDR Target: CNS Penetrant Selective Inhibitor of ATR
SECOND AI DDR TARGET: A CNS PENETRANT SELECTIVE INHIBITOR OF ATR • ATR (ataxia telangiectasia and Rad3-related protein) is a critical kinase that senses and responds to DNA damage by activating repair pathways and orchestrating cell cycle checkpoints. • Cancer cells, which often have high levels of
Slide 14: Rakovina Therapeutics' Drug Development Portfolio
RAKOVINA THERAPEUTICS’ DRUG DEVELOPMENT PORTFOLIO DDR Drug Development Stage Multiple high- value targets Development Indication Drug Lead Pre- Clinical already validated. Pipeline Discovery Optimization clinical Trials PARP kt-3283 PARP- resistant ATM adult & kt-3000 series childhood CYC-E Du
Slide 15: R&D Activities and Catalysts
kt-2000AI * kt-5000AI** Status and Best-in-class PARP-1 Best-in-class ATR selective inhibitor, brain inhibitor, projections penetrant cancer therapy brain penetrant cancer therapy 2024 2025 2026 Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Q1 Q2 Q3 Q4 AI Training R&D activities Ph
Slide 16: Investments in DNA-Damage Response by Multi-National Pharmaceutical Corporations
INVESTMENTS IN DNA-DAMAGE RESPONSE BY MULTI-NATIONAL PHARMACEUTICAL CORPORATIONS RECENT DDR TRANSACTIONS Oct 2023 PARP-inhibitor • $1.5B ($169M upfront) • FDA status at signing: phase 1 License Agreement Jun 2022 ATR-inhibitor • $1.2B ($125M upfront) • FDA status at signing: preclinical License >$25
Slide 17: Market Summary
MARKET SUMMARY EXCHANGE TSX Venture Exchange (TSXV) OWNERSHIP SUMMARY SYMBOL RKV Biopharmaceuticals / Edison Oncology SECTOR / INDUSTRY Oncology Holding Corp. 17.27% 52 WEEK RANGE1 CAD $0.05 - 0.23 Reporting Insiders, SHARES OUTSTANDING 140,792,575 Institution / 5.92% 237,846,947 Retail 64.21% FULLY
Slide 18: Why Invest in Rakovina Therapeutics
WHY INVEST IN RAKOVINA THERAPEUTICS A new paradigm in drug discovery and therapeutic intervention to treat cancer. $18B ADDRESSABLE DDR MARKET Broad cancer application targeting 75% of all solid tumors that harbor a DNA-Damage response defect. BRING-TO-MARKET MANAGEMENT TEAM Deep expertise in drug d
Slide 19: Over 70% of Pharmaceutical Breakthroughs Stem from Small Biotech Companies
OVER 70% OF PHARMACEUTICAL BREAKTHROUGHS [email protected] STEM FROM THE EFFORTS OF SMALL BIOTECH rakovinatherapeutics.com COMPANIES LIKE RAKOVINA THERAPEUTICS. Suite 720, 999 West Broadway Vancouver, British Columbia Canada V5Z TSX.V: 1K5/ 19 RKV
Rakovina Therapeutics — Investor Presentation (May 2025) on 6ix